The mechanisms that control the replication state, latency versus lytic, of human herpesviruses have been under intense investigations. Here we summarize some of the recent findings that help define such mechanisms for Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV-8). For HHV-8, the viral regulator of transcription activation (RTA) is a key mediator of the switch from latency to lytic gene expression in infected cells. RTA is necessary and sufficient to drive HHV-8 lytic replication and the production of viral progeny. The RTA is an immediateearly gene product, it is the initial activator of expression of a multitude of viral and cellular genes that have been implicated in the replication of HHV-8 and pathogenesis of KS. Interactions of RTA with a number of viral promoters, and with a number of transcription factors or transcriptional co-activators are highlighted. Modulation of transactivation, through alternate RTA-protein, or RTA-promoter interactions, is hypothesisized to participate in the selective tissue tropism and differential pathogenesis observed in KS.
Introduction
Human herpesvirus-8 (HHV-8) or Kaposi's sarcomaassociated herpesvirus (KSHV) is the most recent HHV identified. This virus was discovered in 1994 by Chang et al. (Chang et al., 1994 ) using a representational difference analysis (RDA) to identify two unique DNA fragments that were present in an AIDS-Kaposi's sarcoma (KS) tissue. These two 330 and 631 bp fragments were found to have sequence homology to Epstein-Barr virus (EBV) and herpesvirus saimiri (HVS), but represented unique sequences that were part of a new HHV subsequently named the KSHV or HHV-8 (Olsen et al., 1998; Schulz, 1998; Boshoff and Chang, 2001; Jenner and Boshoff, 2002) . The complete viral genome was sequenced (Russo et al., 1996; Neipel et al., 1998) , and was classified as a member of the gamma herpesvirus. Gamma herpesviruses are lymphotropic viruses found to be closely associated with lymphomas . The gamma herpesviruses can be subdivided into two genera: the gamma-1 or lymphocryptoviruses and the gamma-2 or rhadinovirus genus. EBV is the prototype member of the gamma-1 herpesvirus family (Baer et al., 1984; Bornkamm and Hammerschmidt, 2001) . Members of the gamma-2 genus include the HHV-8 (the only human rhadinovirus), HVS, rhesus rhadinovirus (RRV), bovine herpesvirus-4 (BHV-4), equine herpesvirus-2 (EHV-2), alcelaphine herpesvirus-1 (AHV-1), leporid herpesvirus-1 (herpesvirus sylvilagus), and murine herpesvirus-68 (MHV-68) (Telford et al., 1995; Virgin et al., 1997; Neipel et al., 1998; Fickenscher and Fleckenstein, 2001 ; Moore and Chang, 2001 ).
Association of HHV-8 with KS
HHV-8 is associated with all forms of KS. Viral DNA sequences can be detected in classical and endemic forms of KS, as well as transplant-related and AIDS-associated KS Dupin et al., 1995; Huang et al., 1995; Memar et al., 1995; Moore and Chang, 1995; Rady et al., 1995; Buonaguro et al., 1996; Kedda et al., 1996; Alkan et al., 1997) . There is a strong association between the presence of the virus and the development of KS. Serological evidence also suggests that HHV-8 infection is not common in low-risk populations, but much more frequent in individuals at risk for development of KS (Whitby et al., , 1998 Gao et al., 1996; Lefrere et al., 1996; Kedes et al., 1997a) . Furthermore, detection of viral DNA in peripheral blood mononuclear cells (PBMC) of infected individuals was found to predict those who would subsequently develop KS Gao et al., 1996 Gao et al., , 1997 Moore et al., 1996a, b; Russo et al., 1996; Rainbow et al., 1997) . In addition to KS, HHV-8 is associated with several types of lymphopoliferative diseases. HHV-8 sequences can be isolated from many forms of primary effusion lymphomas (PELs) or body-cavity-based lymphomas (BCBL), and from lymph node and other tissues derived from multicentric Castleman's disease (MCD) (Cesarman et al., 1995; Soulier et al., 1995) .
Genomic organization and gene expression pattern of HHV-8
The genomic organization of HHV-8 is similar to other rhadinoviruses, which consists of a central segment of low-GC DNA (L DNA) flanked by multirepetitive high-GC DNA (H DNA) regions (Russo et al., 1996; Schulz, 1998) . The L regions of known rhadinoviruses range from 110 to 130 kb, and contain about 75 reading frames. For HHV-8, a long unique region of 140.5 kb is flanked by two terminal repeats consisting of several high (84.5%)-GC 801 bp repeat subunits (Russo et al., 1996) . More than 80 open reading frames (ORFs) are encoded within the long unique central region of the HHV-8 genome (Moore et al., 1996b) . The ORFs of HHV-8 were assigned the same numbers as their homologous genes in HVS; those genes unique to HHV-8 are given the prefix K (for KSHV) and numbered sequentially. The HHV-8 genome contains genes that are highly conserved among gamma herpesviruses; these genes usually encode either structural proteins or those that are involved in viral replication. The conserved genes are arranged in blocks in the viral genome where they encode the major structural proteins (e.g. ORF25, the major capsid protein), the DNA replication enzymes (e.g. ORF9, the DNA polymerase, and ORF21, the thymidine kinase), the viral glycoproteins (e.g. ORF8, gB, ORF22, gH, and ORF38, gM), and a viral proteinase and assembly protein (ORF17) (Moore et al., 1996b; Russo et al., 1996) . Genes that are found only in other rhadinoviruses and those that are unique to HHV-8 are encoded within 'nonconserved' gene blocks in the viral genome (Neipel et al., 1997) . These genes include several growth factor homologues, for example, viral IL-6 (ORFK2), two macrophage inflammatory protein (MIP)-1a homologues (ORFK4, ORFK6), and one MIP-1b homologue (ORFK4.1) (Nicholas et al., 1997a (Nicholas et al., , b, 1998 . Like HVS, HHV-8 encodes a type-D cyclin (ORF72) that affects cell-cycle regulation, and a vBcl-2 (ORF16) that may contribute to preventing Bax-mediated apoptosis (Neipel et al., 1997) . The HHV-8 genome also contains several unique genes not found in any other rhadinoviruses, including some genes with homologies to interferon regulatory factors (IRFs) (Moore et al., 1996a; Gao et al., 1997) .
Similar to all other herpesviruses, HHV-8 genes can be classified into four broad categories based on their expression kinetics during the viral replication cycle: latent genes, immediate-early (IE) genes, early genes, and late genes. The IE genes are made earliest after primary infection or upon reactivation of the virus into lytic replication. The expression of IE genes does not require de novo protein synthesis and occurs in the presence of protein syntheses inhibitors like cyclohexamide (CHX). IE genes usually encode for regulatory proteins that affect viral or cellular gene expression during infection or reactivation. For HHV-8, several IE transcripts originating from four different regions of the viral genome have been mapped in PEL cell lines; these transcripts were designated as IE-1-IE-4 (Sarid et al., 1998; Zhu et al., 1999; Saveliev et al., 2002) . The IE-1 transcripts encode for the ORF50 and K8 mRNAs, the IE-2 transcribes a 1.7 kb mRNA encoding ORF45, and the IE-3 transcribes a 2.0 kb mRNA encoding for the K4.2. The IE-4 encodes for the 2.6 and 2.1 kb transcripts. The 2.1 kb transcript was predicted to encode for ORF29. The ORF29 gene is spliced and can potentially encode a protein of 687 amino acids (aa). This protein is highly conserved among all herpesviruses and is homologous to the UL15 protein of herpes simplex virus (HSV-1), and has been shown to be involved in the packaging of the viral DNA (Baines et al., 1994) . The 2.6 kb transcript of IE-4 region appears to be bicistronic, encoding for ORF48 by the first exon and shares the same second exon with the 2.1 kb transcript. This transcript is predicted to encode for a 32 kDa protein with an unknown function that is a homologue of the HSV-1 UL15.5. Early gene products are made after the IE genes, but prior to viral DNA synthesis; therefore, their expression is not affected by inhibition of viral DNA replication by agents such as phosphonoacetic acid (PAA). Several HHV-8 early genes have also been identified; they include K8 (positional homologue of EBV BZLF1), K3, and K5 (homologues of the IE gene of BHV-4), vIL-6, vMIPs, polyadenylated nuclear (PAN) RNA, vBcl-2, K12, G protein-coupled receptor (vGPCR), viral dihydrofolate reductase (vDHFR), and thymidylate synthase (Sarid et al., 1998) . Late genes such as ORF65 (small viral capsid antigen, sVCA) usually do not appear until 30 h after induction Zhu et al., 1999) and their synthesis is inhibited by PAA.
HHV-8 latency
A common feature among herpesviruses is their ability to establish latency in the infected hosts (Cohrs and Gilden, 2001) . For the alpha herpesviruses such as HSV-1, initial lytic replication of the virus in epithelial cells upon infection will lead to latent infection of neurons, where the virus will remain latent and establish life-long infection, expressing only a limited number of viral genes known as the latency-associated transcripts (LAT). Latent virus can then be reactivated into lytic replication upon induction (Taylor et al., 2002) . Similarly, gamma herpesviruses such as EBV and HHV-8 also exhibit the latent and lytic phases of infection. Latency enables the virus to escape immune surveillance and to establish persistent infection. In addition, latent infection by HHV-8 and EBV has been implicated to play a major role in tumorigenesis Cesarman, 2002) .
HHV-8 characteristically establishes latent infections in target cells where viral gene expression is highly limited and tightly controlled. The virus can then periodically reactivate to go through lytic replication. Various chemicals, such as tetradecanoyl phorbol acetate (TPA) and n-butyrate, can disrupt the latency of HHV-8 in established PEL cells in vitro (BCBL) and induce lytic viral replication (Arvanitakis et al., 1996; Renne et al., 1996; Yu et al., 1999) . For HHV-8, only five latently expressed genes have been identified. They include the latency-associated nuclear antigens (LANA), the v-cyclin, the v-FLIP, the kaposin, and the vIRF-2 or LANA-2 (Kedes et al., 1997b; Rainbow et al., 1997; Dittmer et al., 1998; Muralidhar et al., 1998; Sadler et al., 1999; Burysek and Pitha, 2001; Saveliev et al., 2002) . How the expression of these genes plays a role in the maintenance of latency and the transformed phenotype still needs to be elucidated. Although latent infection may play a role in sustained viral infection and tumorigeneisis, lytic reactivation has been implicated to be important for KS development Lukac et al., 1999; Martin et al., 1999) . Several lines of evidence have implicated a role for lytic replication, and the activation thereof, in the pathogenesis and induction of tumors by KSHV/HHV-8. First, there is an association between the humoral immune response to HHV-8 infection and the progression to KS . Second, there is an increase in the HHV-8 viral load in PBMC associated with progression from the asymptomatic phase to KS (Ambroziak et al., 1995) . Third, treatment of individuals dually infected with HIV-1 and HHV-8, and at high risk for development of KS, with ganciclovir, a drug that is active only against HHV-8 lytic replication, leads to a decreased incidence of KS (Martin et al., 1999) . Fourth, most KS tumor cells are found to be latently infected by HHV-8, and HHV-8 infections of spindle cells are predominantly latent; however; a small number of infected tumor cells undergo spontaneous lytic replication Staskus et al., 1997; Reed et al., 1998; Staskus et al., 1999) . Finally, lytic replication is likely to be important in the spread of HHV-8 from the lymphoid compartment, where it is localized early in disease, to endothelial cells where tumors are most frequently observed. Lytic reactivation is likely to enable the spread of viruses from the lymphoid reservoir to the endothelial sites and contributes to the development of KS. Associated with activation of HHV-8 to lytic replication is the expression of a number of viralencoded cellular homologues with known cytokine or cytokine-receptor signal transduction potential. These cellular homologues include vIL-6, vGPCR, and vMIP-I and vMIP-II (Russo et al., 1996; Neipel et al., 1997; Kirshner et al., 1999) . These proinflammatory mediators have been suggested to play a key role in the autocrine and paracrine maintenance of KS tumor. Several of these gene products have also been demonstrated to induce neoangiogenesis Arvanitakis et al., 1997; Boshoff et al., 1997; Bais et al., 1998) . Thus, the control of latent to lytic replication in HHV-8-infected cells, and the expression of lytic gene products could play a key role in KS disease pathogenesis.
Molecular events involved in gamma herpesviruses switch from latency to lytic replication
The molecular events and genes that control latent to lytic switching have been studied best in EBV-infected B lymphoma cells. The reactivation of EBV from latency was found to be associated with two IE genes, BZLF1 and BRLF1, encoding for ZTA and regulator of transcription activation (RTA), respectively, both are transcriptional activators that trigger the lytic cascade of viral replication (Takada et al., 1986; Zalani et al., 1996; Ragoczy and Miller, 1999) . These two genes are expressed simultaneously during lytic induction (Bornkamm and Hammerschmidt, 2001 ). Expression of ZTA in lymphocytes is sufficient to trigger the lytic cycle (Takada et al., 1986) . However, it has recently been reported that RTA alone is also able to disrupt latency in epithelial cells and certain B-cell lines (Zalani et al., 1996; Ragoczy and Miller, 1999) . In those cells, RTA activates ZTA expression by upregulating the promoter of BZLF1, and therefore stimulates early gene expression, DNA replication, and late gene expression (Quinlivan et al., 1993; Zalani et al., 1996; Ragoczy and Miller, 1999) . Moreover, RTA is a competent transactivator of a subset of downstream lytic cycle genes, some of which respond mainly to RTA, whereas others require the concomitant activities of both RTA and ZTA.
EBV RTA is a sequence-specific DNA-binding protein that binds to the consensus sequence 5 0 -GNCCN 9 GGNG-3 0 (Gruffat et al., 1990; Gruffat and Sergeant, 1994) , named RRE (RTA responsive element), possibly by recognizing the two adjacent major grooves of the DNA. The DNA-binding domain of EBV RTA protein has been localized within the N-terminal 280 aa. EBV RTA binds to RRE as a homodimer; the dimerization region has been mapped to the N-terminal 232 aa (Manet et al., 1991) . A potent acidic activation domain has been identified at the C-terminus of RTA, from aa 520 to 605, and contains three partially overlapping hydrophobic motifs. These motifs can be aligned with the activation domains of a number of yeast and mammalian transcription activators, which also exhibit a conserved pattern of hydrophobic residues. Substitutions of these hydrophobic amino acids were found to impair severely transactivation (Hardwick et al., 1992) .
In HVS, two genes, ORF50 and ORF57, which encode transcription-regulatory proteins, have been identified. ORF57 functions at the post-transcriptional level, and ORF50, a homologue of EBV RTA protein, is a sequence-specific transactivator (Fickenscher and Fleckenstein, 2001) . Two transcripts are encoded by the HVS ORF50 gene; the first transcript contains a single intron, is spliced, and can be detected early during lytic viral replication, whereas the second one is produced from a promoter within the second exon and is expressed later in infection (Whitehouse et al., 1997) . A consensus target sequence, 5 0 -CCN 9 GG-3 0 , is required for transactivation by the HVS ORF50 (Whitehouse et al., 1997) . The expression of the ORF57 gene was demonstrated to be upregulated by the ORF50 product at the RNA level (Whitehouse et al., 1998b) . Furthermore, the ORF57 mRNA was found to downregulate subsequently ORF50 via the presence of its intron and represses the transactivating capabilities of ORF50 (Whitehouse et al., 1998a) . These observations suggest a feedback mechanism modulating gene expression in HVS, whereby ORF50 transcription is downregulated by the ORF57 product, which ORF50 specifically transactivates. A C-terminal activation domain containing several conserved hydrophobic domains have also been identified in the HVS ORF50 protein, and these hydrophobic residues are essential for the ORF50 transactivation function. The activation domain of HVS ORF50 has also been shown to be required for the interaction between the ORF50 protein and the basal transcription factor TATA-binding protein (Hall et al., 1999) .
In contrast to EBV, the switch between latency and lytic cycle gene expression in HHV-8 can be initiated by the EBV RTA homologue encoded by the HHV-8 ORF50 gene. The HHV-8 RTA, which is also known as the ORF50 or ART, is a replication and transcription activator. HHV-8 RTA was initially identified based on positional analogies with EBV and HVS, and by sequence homology (Sun et al., 1998) . The ORF50 gene is one of the earliest IE genes induced upon viral reactivation (Sarid et al., 1998; Sun et al., 1999; Zhu et al., 1999) . Expression of the RTA mRNA is resistant to protein synthesis inhibitors like CHX, indicating that de novo protein synthesis is unnecessary for the production of RTA in response to the appropriate stimulus or environmental conditions. Northern blot analysis of total RNA from TPA-induced PEL cells (BCBL-1 cells) showed that the ORF50 transcript can easily be detected within 1 h of TPA induction (Lukac et al., 1999) , and was characterized as the major transcript encompassed by the major IE region (IE1) (Saveliev et al., 2002) . The expression of RTA precedes the expression of all other CHX-resistant messages and those of PAA-resistant but CHX-sensitive early genes. In addition, RTA has been shown to be sufficient for the ectopic reactivation of lytic replication in PEL cell lines (Lukac et al., 1998 (Lukac et al., , 1999 Gradoville et al., 2000) . Such disruption of latency has been shown to lead to the complete replication of nascent, infectious virus particles with kinetics that are consistent with stimulation by chemical means (Gradoville et al., 2000) . The difficulties in propagating HHV-8 in a cell culture system have Figure 1 Schematic representation of the ORF 50 gene locus and the transcripts encoded by ORF50 (derived from the studies by Lukac et al. (1999) , Zhu et al. (1999) , Saveliev et al. (2002) . The different HHV-8 genes shown in this locus include ORF49, ORF50, K8, and K8.1. Three spliced mRNAs that can potentially encode the RTA are shown. RTA is encoded by two exons, which are shaded in gray. The three mRNA species can also encode three different versions of the K8 protein, which is shown in black. The untranslated regions of the three mRNAs are not shaded. Two other transcripts that are made antisense and overlaps with the ORF50-coding region are also shown. T3.0 represents the 3 kb antisense and T1.2 represents the 1.2 kb antisense transcript. The arrows represent the direction of the sense transcripts encoded by the three ORFs. AUG represents the translation start sites, and UGA and UAG represent the termination codons for the different ORFs. The numbers represent the position of the viral genome. SD and SA represent splice donors and splice acceptors, respectively
The role of Kaposi's sarcoma-associated herpesviruses JT West and C Wood made it difficult to demonstrate the role of RTA in primary infection; however, the closely related RRV ORF50/RTA is expressed in de novo infection and appears to mediate lytic replication (DeWire et al., 2002) . Taken together, these properties define RTA as an IE regulatory gene.
The HHV-8 ORF-50 mRNA Multiple transcripts were found to be encoded by the ORF50 region; the main transcript is a 3.6 kb mRNA that encodes the entire RTA. In addition, a downstream gene, K8 was also found to be encoded within the same RNA species (Figure 1) . Three minor RNA species of about 7.0, 3.0, and 1.2 kb were transcribed from the ORF50 gene but were found to be complementary to the ORF50 3.6 kb mRNA. The 7.0 kb mRNA species has not yet been characterized, but the 3.0 and 1.2 kb transcripts do not appear to encode for any large ORFs. Since these transcripts are made as antisense to the ORF50 3.6 kb mRNA but appear to express at the same time during viral reactivation, whether these RNAs play a regulatory role on ORF50 expression at the RNA level needs to be determined.
The ORF50 3.6 kb mRNA was found to consist of several mRNA species. The major species consists of five exons, which encodes the ORF50 and ORF K8 (Figure 1 ). The K8 ORF is highly spliced and was designated as K8a. This spliced form of K8 showed 21.6% amino-acid sequence homology to the ZTA proteins of EBV. The predicted protein contains a bZip domain near the carboxyl terminus and an acidic domain at the amino terminus. The other minor species of mRNA also encodes the ORF50, but the K8 ORF is either unspliced or singly spliced, and both K8 ORFs are predicted to lack the bZip domain. In addition, another species of ORF50 mRNA of about 3.4 kb was identified and was found to contain the ORF 50 K8 and K8.1 ORFs (Lukac et al., 1999) . The K8.1 ORF encodes for a virion-associated glycoprotein that is involved in infection and in the binding to the cellular receptor (Chandran et al., 1998; Raab et al., 1998; Li et al., 1999) .
The RTA protein
Based on the analysis of the ORF50 mRNA, the HHV-8 RTA protein is encoded by two exons, which are common among all ORF50 mRNAs. The first small 5 0 ORF50 exon provides the AUG for translation. The transcript is bicistronic with K8 and polyadenylated, it can potentially encode for a protein of 691 aa, and is predicted to have a molecular mass of 73.7 kDa. However, the expressed protein when analyzed by Western blotting appears to be about 110 kDa, suggesting that RTA could be modified post-tranlationally by phosphorylation or by other mechanisms (Lukac et al., 1999) . Indeed the RTA amino-acid sequence reveals multiple potential phosphorylation sites, including a C-terminal domain that is highly serine and threonine rich, but it is unclear what residues (Ser/Thr or Tyr) are modified or which enzymes participate in the modification. The structure of the HHV-8 RTA is shown in Figure 2 . RTA lacks any significant homology with cellular proteins but is functionally and to a lesser degree genetically homologous to EBV ZTA, and the RTA proteins from HVS and MHVg68 (Wu et al., 2000) . In addition, the overall amino-acid homology of HHV-8 RTA to EBV RTA is about 20%.
The RTA protein consists of an N-terminal DNAbinding domain, a central dimerization domain, a C-terminal acidic activation domain, and two nuclear localization signals (NLS) (Figure 2 ). The DNA-binding domain of RTA is located at the amino terminus from aa 1 to 530. A deletion mutant of the activation domain sequences (aa 531-691), containing only the DNAbinding domain, has been shown to be transdominantnegative mutant that maintains DNA-binding activity for RTA responsive promoters but no longer activates lytic gene expression. This protein, RTA DNA-binding domain (RDBD), has been particularly useful in defining promoter interactions of RTA that inhibited ORF50 function (Lukac et al., 1999) . The activation domain is located at the carboxyl terminus of the protein, this region is highly acidic (aa 486-691) and contains numerous charged amino acids (Lukac et al., 1999; Seaman et al., 1999) . This region also contains four repeated units of a highly hydrophobic domain, known as activation domains 1-4 (AD1-AD4), with sequence homology to other transcriptional factors such as VP16 domain A (Lukac et al., 1999) . These characteristics suggest that HHV-8 RTA is a member of a family of transcriptional factors that regulate gene expression.
RTA interacts with various promoters and factors to mediate lytic activation
RTA has been shown to regulate and transactivate a number of downstream viral genes that function in lytc replication (Sun et al., 1998 Lukac et al., 1999; Zhu et al., 1999; Gradoville et al., 2000; Saveliev et al., 2002) . Most studies of RTA promoter activation have been carried out using transient transfection of promoter/reporter constructs along with constructs that express RTA. Mutations of RTA and of its target promoters have been used to map functional domains of RTA and to define RRE. Additionally, purified or in vitro translated RTA, and mutants thereof, have been used in electrophoretic mobility shift assays (EMSA) to demonstrate the direct binding of RTA to DNA in some of the promoters. Specificity of binding is evidenced by the reduction of binding in the presence of sequencespecific competitor DNA or protein. However, RTA does not recognize the same sequence element in all responsive promoters. This diversity of recognition suggests that on some promoters, other viral and host factors may direct or augment DNA binding and may influence the diversity of RTA transactivation (Seaman et al., 1999; Lukac et al., 2001; Sakakibara et al., 2001; Wang et al., 2001a; Chang et al., 2002; Deng et al., 2002b; Saveliev et al., 2002) .
The activation of ORF57 and K8 expression involves direct promoter binding of RTA
The HHV-8 ORF57 gene product is a 448 aa transcriptional regulator that functions in control of both early and late lytic gene expression (Russo et al., 1996; Sarid et al., 1998; Duan et al., 2001) . ORF57 is a functional homologue of the EBV SM or Mta gene that plays an important role in the expression of viral genes, particularly structural genes, by facilitating the transport of the mRNAs to the cytoplasm (Nicholas et al., 1988; Kenney et al., 1989a, b) . The expression of ORF57 is stimulated by the addition of TPA and is upregulated by the expression of RTA. In our initial investigation of the RTA activation of ORF57, we showed that RTA activated ORF57 promoter-directed expression of a reporter gene (luciferase) (Duan et al., 2001) . Comparison of the HHV-8 sequence 5 0 to the ORF57-coding region revealed four motifs related to RRE identified in HVS promoters. Removal of all four sequences had little effect on RTA-activated expression from the ORF57 promoter; however, a 40 bp region between nt 81904 and 81944 was found to be essential for RTA responsiveness. A significant 16 bp homology between the ORF57 region and the 5 0 sequences preceding the HHV-8 K8, basic leucine zipper (bZip) gene were reported (Wang et al., 2001a) ; moreover, a near-identical 25 bp sequence was subsequently described by Lukac et al. (Lukac et al., 2001) . Mutational analyses revealed that both the K8 and ORF57 sequences were responsive to RTA and conferred RTA responsiveness to heterologous promoters. The RTA responsiveness required a functional activation domain in RTA since proteins that bound the 16 bp sequence in either promoter DNA, but lacked the activation domain, were nonfunctional.
Lukac et al. have further shown that RTA protein produced from baculovirus in Sf9 cells or from bacterial expression bound to the ORF57/K8 promoter element (a 12-base palindrome sequence) (Figure 3) , the deletion of which ablated RTA responsiveness (Lukac et al., 2001) . The two halves of the palindrome were not equivalently required for activity. These findings suggest that the linear DNA sequence in the ORF57 and K8 promoter region is more critical than the palindromic nature of that sequence. In addition to the 25 bp region conferring RTA responsiveness (defined as 50RE 57 ), sequences TATA-proximal to the 50RE 57 within the promoter were also sensitive to mutation, and any (Song et al., 2001; Chang et al., 2002) . The overall identity between the ORF57 and K8 RTA-responsive promoter regions is shown boxed and the sequences that contribute to the palindrome are shaded (Duan et al., 2001; Lukac et al., 2001) . The sequence of the RTA-responsive element in the HHV-8 IL-6 is presented as described in Deng et al. (2002b) . The Oct-1-binding site within the RTA promoter that is implicated in the autoregulation of RTA expression is shown boxed The role of Kaposi's sarcoma-associated herpesviruses JT West and C Wood mutation that affected RTA DNA binding blocked promoter activation. Nevertheless, these ORF57 and K8 promoter elements are unique since comparison of the entire HHV-8 genome did not reveal any other instance of the 12-base palindromic sequence, nor is any significant homology present in other RTA-responsive viral promoters.
The role of RTA in PAN RNA and K12 expression
The HHV-8 PAN RNA is an enigma. PAN is the most abundant viral transcript of HHV-8 and its expression can account for up to 80% of isolated cDNA clones derived from induced PEL cells (Sun et al., 1996; Zhong et al., 1996) . PAN contains features of both cytoplasmic-targeted mRNA (polyadenylation) and of small nuclear RNAs (no reading frames longer than 61 aa). PAN codon usage is not indicative of higher eukaryotes, nor does the RNA associate with polysomes. Nevertheless, the function of PAN RNA in the virus life cycle has not been defined.
The RTA-responsive region of the PAN promoter (PANp) does not share demonstrable homology with that of ORF57 or K8. A region of the PANp corresponding to nucleotides À70 to À46 [numbering according to Chang et al. (2002) ] was found to be essential to RTA activation of PAN expression. The K d of the RTA association with PANp has been reported to be in the nanomolar range (Song et al., 2001 (Song et al., , 2002 , suggesting that the high affinity of RTA for the PANp is likely responsible, in part, for the abundance of PAN RNA in cells expressing lytic transcripts. Song et al. (2002) have carried out a thorough investigation of the RTA-PANp interactions using chemical modifications, mutagenesis, and reporter assays to define the binding motif in PANp (Figure 3) .
Using similar methods Chang et al. (2002) showed that the 490 aa RDBD was required for recognition and lytic activation of the PANp or the promoter for K12, another gene whose expression is upregulated in the lytic cycle. This activation was also evident when the RTAresponsive sequence was fused to the heterologous adenovirus E4 promoter demonstrating that RTA activation was dependent upon the RRE but independent of binding sites for cellular transcription factors that were distinct between PANp and the E4 promoter. A core 16-base element (Figure 3) is shared between the two promoters, the alteration of which results in ablation of activation. Optimal expression requires a variable number of additional bases downstream of this element, and the homology within this region is considerable. K12 also appears to require additional bases on the 5 0 end of the core element that are unnecessary for PAN activation. It should be noted that while the DNA-binding element defined as essential for RTA binding and activation of ORF57 and K8 is not present in PAN or K12, the reciprocal is also true.
These findings suggest that RTA interacts, either directly or indirectly, with distinct promoter sequences (a function that is infrequently observed in transcriptional activator proteins) or that the RTA recognition is markedly degenerate. Another plausible explanation for the binding of different promoters is the interaction of RTA with cellular coactivators of expression that alter the capacity and specificity for RTA promoter recognition.
The role of RTA in vIL-6 expression and function Virally encoded proinflammatory cytokines and cytokine receptors are implicated in the pathogenesis of the various disease states associated with HHV-8 infection such as KS, PEL, and MCD (Ensoli et al., 1992; Moore et al., 1996a; Nicholas et al., 1997b; Aoki et al., 1999; Liu et al., 2001) . The role of HHV-8 IL-6 (ORF K2) in HHV-8-induced neoplastic disorders seems likely for a number of reasons. vIL-6 is frequently detected in PEL patient effusions. Both human and vIL-6 stimulate Bcell proliferation and differentiation, and both induce angiogenesis (Taga and Kishimoto, 1997) . vIL-6 shares approximately 25% amino-acid identity with the cellular version of the same protein (Aoki et al., 2000a) . vIL-6 activates both the Ras-/MAP kinase and the JAK/ STAT signal transduction pathways (Molden et al., 1997; Osborne et al., 1999) . vIL-6 has also been demonstrated to upregulate the expression of vascular endothelial growth factor (VEGF), the presence of which might provide a mechanism for increased vascular permeability and fluid accumulation observed in PEL patient body cavities (Aoki et al., 1999 (Aoki et al., , 2000a . VEGF may also contribute to the angiogenesis and endothelial outgrowth observed in MCD (Aoki et al., 2000a; Moore et al., 1996a) .
Human IL-6 (hlL-6) signaling requires both the gp130 and the IL-6Ra components of the IL-6 receptor, whereas vIL-6 can signal through the gp130 subunit alone (Molden et al., 1997; Taga and Kishimoto, 1997; Wan et al., 1999) . The affinity of vIL-6 for gp130 is significantly less than the affinity of hIL-6 for the complete receptor complex (Aoki et al., 2001) . The widespread expression of gp 130 offers some explanation for the induction of the distinct disease states attributed to HHV-8 infection.
Reactivation of latent cells results in high-level expression of vIL-6. Deng et al. (2002b) have recently demonstrated that the transcription of vIL-6 expression is activated by RTA. RTA has been shown to bind to a 26 bp element in the promoter DNA (Figure 3) . Binding affinity for the vIL-6 RRE was shown to be similar to that of ORF57 by binding-competition gel shift analysis. Nevertheless, no significant homology between this RTA-binding element and those identified in the PAN, K8, K12, or ORF57 promoters was identified.
RTA has also been demonstrated to interact with activators downstream of either the human or viral IL-6 signal transduction pathways that promote viral persistence via the STAT3 protein (Moore et al., 1996a; Nicholas et al., 1997b; Aoki et al., 2000a; Gwack et al., 2002) . STAT proteins are a diverse group of cytoplasmic signal transducers that upon stimulation by cytokines or growth factors form dimers induced by tyrosine phosphorylation (Schindler and Darnell, 1995; Darnell, 1997; Bromberg and Darnell, 2000) . Tyrosine phosphorylation stabilizes the association between two STAT monomers through the interaction of the phosphotyrosine with the SH 2 domain. Activated STAT dimers then translocate to the nucleus where they bind DNA elements to activate gene expression (Darnell, 1997) . A number of proteins, including some implicated in tumorigenesis, stimulate proliferation and block apoptosis via STAT signaling. Moreover, constituitively active STATs are associated with various lymphoid or myeloid leukemias and with some EBV-transformed cell lines (Migone et al., 1995; Weber-Nordt et al., 1996 .
HHV-8 RTA activates STAT3-mediated transcription in promoter-reporter activation assays without inducing tyrosine phosphorylation (Gwack et al., 2002) . The interaction appears to be direct since RTA was demonstrated to interact with various regions of STAT3, including the N-terminal dimer-dimer interaction/CBP-binding motif, the DNA-binding c-Jun interaction domain, and the SH 2 phosphotyrosine recognition activation domain. RTA has been proposed to stabilize STAT3 dimers, and dimerization appears to be the essential criterion for STAT3 transcriptional activation. RTA mutants that fail to stimulate STATactivated reporter gene expression also fail to induce STAT dimerization. The cytokine IL-6, and others, are known to provide an activation signal for STAT3 and to promote its translocation into the nucleus (Smith and Crompton, 1998; Schumann et al., 1999; Zhang et al., 2000) . Therefore, in the presence of IL-6 and other mediators, a significant proportion of STAT3 will be in the nucleus, thereby increasing the probability of interactions with RTA. The expression of the HHV-8 vIL-6 might also induce the nuclear localization of STAT3 and promote the likelihood of interactions with RTA. The seemingly critical role of both human and vIL-6 in HHV-8-associated tumors, and the existence of RTA control on the expression of both are highly suggestive of a relationship between RTA and IL-6 in viral pathogenesis.
Interestingly, RTA also appears to specifically activate hIL-6 expression (Deng et al., 2002a) . While high levels of hIL-6 often associated with latent HHV-8 PEL lines could be a function of LANA activation of hIL-6 expression , the role of RTAactivated hIL-6 and vIL-6 may be important in MCD lesions where more infected cells express lytic HHV-8 antigens Parravicini et al., 2000) .
RTA binds to specific but unrelated sequences in a number of promoters, notably PAN and ORF57; nevertheless, there are other RTA-responsive genes, such as vIL-6 and hIL-6, that lack either of these binding sites (Figure 3 ). This implies that activation of these promoters may result from RTA interaction with other cellular or viral proteins that mediate the DNA-transcriptional complex interaction. One such cellular factor could be NF-kB.
Recently, Roan et al. (2002) attempted to determine which cellular genes were activated by RTA in the absence of all other viral factors. They demonstrated that RTA-induced expression and secretion of IL-6, did not require many of the transcriptional factor-binding sites in the IL-6 promoter, including that for NF-kB. The expression from the IL-6 promoter was inhibited by expression of the RelA subunit of NF-kB. Activation was resistant to I-kBa inhibition and was therefore thought to be independent of NF-kB RelA subunit induction (Barkett and Gilmore, 1999; Gilmore, 1999; Gugasyan et al., 2000) . Their results attribute yet another level of transcriptional control to RTA by identifying a relationship between RTA and the transcriptional complex NF-kB. As will be discussed further, a critical component of cellular transactivation on many promoters is the cAMP-response elementbinding protein (CREB)-binding protein (CBP). Since NF-kB requires CBP for coactivation of responsive promoters (Sheppard et al., 1999) , the authors suggest that their results could be explained by RelA sequestration of CBP, thereby making CBP unavailable for RTA interactions. This hypothesis is consistent with the limiting quantity of CBP in cells and the concept that sequestration of CBP would not require an NF-kBbinding site in order to be effective (Kamei et al., 1996) . Based on these observations, it was proposed that NFkB (via Rel A) activating factors could suppress the ability of RTA to induce viral and cellular genes, and might be expected to have consequences for pathogenesis linked to lytic reactivation.
The autoregulation of RTA expression
In the previous sections we described the requirements for the interaction of RTA with viral promoters involved in the activation of HHV-8 lytic replication. Recently, in an effort to describe which HHV-8 genes are regulated by RTA, Sun and colleagues revealed that RTA regulates its own expression (Deng et al., 2000) . A 3.0kb promoter region 5 0 to the coding region of ORF50 was used in reporter assays to test the responsiveness of the RTA promoter to stimuli such as TPA, butyrate, and RTA. The levels of RTA activation varied based on the cell type (BCBL-1, 144-fold; 293 T, 40-fold), but was independent of the presence of viral or B-cell factors for induction. The reported levels of expression contrast with the modest values for RTA-autoactivation previously reported by Seaman et al. (1999) (2.7-fold) in BCBL-1 cells. It has been suggested that differences in the assay methodologies and in the length of the promoter sequence employed (Seaman et al. used a 655 bp fragment) could be responsible for these discrepancies. Similarly, Sakakibara et al. (2001) have described modest activation of the RTA promoter through the interaction of the transcription factor Oct-1 with its cognate-binding sequence between À227 and À208 in the RTA promoter (Figure 3) . A direct RTAOct-1 interaction did not appear to be involved and its reduced level of activation, in comparison with that described by Sun et al., may also reflect the size of the 5 0 region included prior to the RTA transcriptional start site.
Recently, Chen et al. (2001) have proposed another mechanism that may regulate RTA expression. Methylation of CpG dinucleotide sequences within promoter regions is generally associated with transcriptional quiescence (Figure 4 ). This repression can be mediated by two methyl-CpG-binding proteins, MeCP1 or MeCP2. Methylation may play a role in chromosome reorganization since MeCP2 can displace histone H1 from nucleosomes, and also has recruitment activity for histone deacetylases (HDAC) that also promote silencing of promoter regions (Cross et al., 1997; Nan et al., 1996 Nan et al., , 1997 Nan et al., , 1998 Jones et al., 1998; Wade et al., 1999) . Thus, there exists a link between two mechanisms of gene silencing, methylation and deacetylation, and as we will discuss in the next section, HHV-8 has developed mechanisms to counter deacetylation. Addition of inhibitors of methylation such as 5-azacytidine can trigger lytic replication. It has been suggested that methylation of the RTA promoter region during latency promotes the association of transcriptional repressors and HDAC. Interestingly, butyrate, a known activator of lytic replication, is an inhibitor of HDAC, and conversely, TPA is an inducer of histone acetylases (HAT) such as CBP/p300 (Masumi et al., 1999) (Figure 4) . Therefore, both inducers of HHV-8 lytic replication are affecting the acetylation state of the RTA promoter that is in turn dependent on methylation. This finding has been translated to symptomatic KS patients whose RTA promoters were shown to be less methylated than the same promoter regions from healthy asymptomatic individuals. Such findings imply that the control of latency and of lytic switching is a function of chromosomal architecture, and will involve interplay between viral RTA and host factors that regulate chromatin methylation and acetylation.
RTA and the transcriptional coactivators CBP and p300
The acetylation state of histones is correlated with the transcriptional activity of promoters with which those histones are associated (Wolffe, 1996; Giles, 1998) . Acetylation, carried out by HAT, promotes a more open chromatin structure where transcription factors are free to bind (Figure 4) . Conversely, deacetylation by HDAC promotes tightly packed nucleosomes that are, therefore, unable to participate in the gene expression. Two of the best-described activators of histone acetylation are the cAMP-response element-binding protein (CREB)-binding protein (CBP) and p300 (Bannister Figure 4 Promoter methylation and acetylation in the regulation of RTA and other HHV-8 promoters. The upper panel depicts a transcriptionally active promoter where the intrinsic HAT activity of CBP has acetylated the histones leading to RTA expression and lytic replication. RTA appears to promote this process and its own expression through a mechanism that may involve direct interaction with CBP, and perhaps Oct-1 and other transcription factors such as STAT3 or c-Jun. Latency is promoted by increases in promoter methylation and by proteins such as the MeCP that recognize methylated residues, displace histone H1, and recruit HDAC. The apparent mechanisms of various chemicals that induce lytic replication are shown. TPA is tetradecanoyl phorbol acetate and Kouzarides, 1996; Ogryzko et al., 1996) . These transcriptional coactivators are structurally and functionally homologous to one another, and both possess intrinsic HAT activity. CBP interacts with activated CREB, c-Jun, c-Fos, adenovirus E1A, SRC-1and p53 (Eckner et al., 1994; Bannister and Kouzarides, 1995; Kamei et al., 1996; Yang et al., 1996; Giles, 1998; Martinez-Balbas et al., 1998) . The direct interaction of CBP with HHV-8 RTA in the activation of lytic replication has recently been reported by Choe and colleagues (Hwang et al., 2001; Gwack et al., 2001a) . This interaction requires the N-terminal basic domain, and a conserved LXXLL (aa 593-597) motif in the RTA activation domain ( Figure 5 ); this motif is also found in transcriptional coactivators (SRC-1) that bind to nuclear receptors as well as CBP (Heery et al., 1997) . The LXXLL motif has also been described in other proteins as an interaction domain for the hydrophobicbinding pocket of p300/CBP (Westin et al., 1998) . RTA was shown to bind CBP in vitro and in vivo through interaction with the C/H3, Zn-finger-containing domain and to a lesser extent the C-terminal activation domain of CBP. The adenovirus E1A protein bound the CBP C/ H3 domain and repressed RTA activity in a dosedependent manner, further implying the functional significance of the RTA CBP interaction. In contrast to E1A, c-Jun, which binds the CBP kinase-induced activation domain (KIX) (Kwok et al., 1994; Kamei et al., 1996) , stimulated RTA activity in a dosedependent manner, suggesting that c-Jun and RTA bind different domains in CBP and such binding is not competitive.
HDAC was shown to repress RTA activity by binding directly to the proline-rich sequences in the RTA central domain between aa 301 and 449. Specific inhibition of HDAC by trichostatin A (TSA) derepressed the inhibition of RTA and stimulated RTA-directed gene expression. Mutations that eliminated the RTA sequence between 301 and 449 aa were no longer responsive to TSA derepression, thereby providing evidence of the direct interaction between HDAC and RTA in cells. These findings suggest a strong relation between RTA and CBP, in the methylation and acetylation of target promoters.
HHV-8 RTA and p53
The transcriptional activator p53 binds to the Cterminal activation domain of CBP where RTA is also thought to bind ( Figure 5) (Gwack et al., 2001a) . The lower panel shows the domains of CBP; the nuclear receptor domain is responsible for interactions because of signal transduction events; KIX -the kinase-induced activation domain mediates interaction with CREB and c-Jun; HAT is the histone acetyltransferase domain; Zn finger is the site of high-affinity RTA interaction as well as for the RTA competitor E1A, and TAD is the transactivation domain
The role of Kaposi's sarcoma-associated herpesviruses JT West and C Wood 1997; Snowden and Perkins, 1998; Manteuffel-Cymborowska, 1999; Grossman, 2001 ). Since cellular transcription is often modulated by viral transcription activators by direct or indirect effects on CBP, Gwack et al. (2001b) tested whether RTA might interfere with p53-activated promoters and demonstrated that RTA inhibited p53-mediated gene expression via interaction with CBP. RTA mutants that did not bind CBP failed to inhibit p53 activation on a variety of p53-sensitive promoters, whereas RTA constructs that contained both CBP interaction domains inhibited p53-directed expression. No interaction between p53 and RTA was evident from two-hybrid screening or from attempts to coprecipitate the proteins. In an evaluation of the effect of RTA on p53 function, CBP-binding-competent-RTA was shown to block p53-induced apoptosis in SAOS2 cells whereas RTA mutants that failed to bind CBP did not. In summary, HHV-8 RTA acts not only as a transcriptional activator to induce lytic replication, but also as a regulator of cellular transcription and perhaps apoptosis. Thus, the seminal role of CBP in RTA function relative to the regulation of promoter methylation/demethylation, and acetylation/deacetylation is increasingly evident.
KSHV RTA-binding protein (K-RBP) and RTA coactivate viral expression
Identification of cellular proteins that coordinate with RTA and characterization of the mechanisms whereby such host-viral protein complexes mediate the switch from HHV-8 latency to lytic replication is an important step in understanding the virus life cycle and pathogenesis. In addition to CBP/p300 it is likely that other cellular proteins participate in RTA function. We recently isolated one such protein, K-RBP, from a yeast two-hybrid screening of an EBV-transformed B-cell library using RTA as 'bait' (Wang et al., 2001b) . K-RBP is a 554 amino-acid protein of unknown cellular function that contains an N-terminal Kreupel-associated box (KRAB) and a C-terminal Zn-finger domain with 11 C2H2 motifs. K-RBP has no generalized effect on transcription, but acts instead as a stimulatory cofactor with RTA. The interaction with RTA was confirmed by coimmunoprecipitation. We further showed that the K-RBP Zn-finger domain was required for the association with RTA since in cotransfections with K8 or ORF57 promoter-reporter constructs, KRBP lacking this domain did not synergistically activate RTA induction of expression of the reporter. Moreover, mutant K-RBP was not pulled down using immobilized RTA whereas the full-length protein was efficiently detected. Since many KRAB family proteins bind to DNA in order to mediate transcriptional repression via their KRAB domain, the mechanism whereby K-RBP enhances RTA activation must be quite different. It is not yet clear whether K-RBP binds DNA directly or whether such binding involves the Zn-finger domain, as is the case for many KRAB family members (Abrink et al., 2001; Gebelein and Urrutia, 2001 ).
RTA as a functional analog of cellular Notch
Using a similar yeast two-hybrid methodology, Liang et al. (2002) have described a second RTA-interacting protein termed RBP-Jk. RBP-Jk is a sequence-specific DNA-binding protein in the CSL/CBF-1 family that is normally thought to repress transcription in response to Notch pathway signaling (Mumm and Kopan, 2000) . CSL family proteins recruit corepressor proteins via their interaction with the CSL central domain (aa 179-361 in RBP-Jk) (Hsieh et al., 1999) . These corepressors, in turn, recruit HDAC that induces promoter silencing. Regulation of CSL family members is mediated by Notch transmembrane receptors, that induce a proteolytic cascade to release the Notch intracellular domain (NCID) in response to interaction with ligand (Weinmaster, 2000) . NLS sequences in the NCID mediate transport to the nucleus where the peptide interacts with RBP-Jk. This interaction appears to involve the central repressor domain (CRD) that is also the target for RTA interaction.
RTA binding may displace repressor proteins from RBP-Jk or could result in recruitment of the NCIDactivation domain (which activates HAT) to RTA. Liang et al. proposed that RTA acts as a functional homologue of Notch (NCID) with the addition of DNA-binding capability. The addition of intrinsic DNA binding is likely responsible for the differences in genes activated by RTA in contrast to the Notch cellular pathway. Interestingly, EBV latency proteins EBNA-2 and EBNA-3 have been shown to interact with RBP-Jk (Grossman et al., 1994; Hsieh and Hayward, 1995; Johannsen et al., 1995 Johannsen et al., , 1996 . EBNA-2 does not bind to DNA but does promote B-cell proliferation. Interaction of EBNA-2 with the RBP-J6 CRD in a region, coincident with that mapped for RTA interaction, results in derepression of RBP-J6 bound promoters. EBNA-3 appears to function in the converse (Waltzer et al., 1996; Zhao et al., 1996) . There is, however, little sequence homology between EBNA-2 or -3 and HHV-8 RTA. Moreover, the EBV proteins are expressed in latency while RTA is an IE product.
The activation of cytokines (viral or cellular) may have profound consequences for HHV-8 replication and pathogenesis. Since some of these cytokines can stimulate Notch, it is reasonable to hypothesize that Notch-like activity in RTA promoter activation may provide a level of environmental 'sensing' to the HHV-8 latency/lytic switch. This switch may then favor one outcome or the other based on the presence or absence of particular extracellular ligands.
Summary
HHV-8 RTA is a key transcriptional regulator that plays an important role in controlling the switch from viral latency to lytic replication, and is sufficient to drive the viral lytic cascade to completion and induce the production of encapsidated virions. The RTA protein is made as an IE gene product, it autoregulates its own expression, and activates the transcription of various viral and cellular genes. The exact mechanisms whereby HHV-8 RTA activates expression are still not clear, but two possibilities can be supported by the existing data. 1) RTA can transactivate by either binding directly to target gene promoters through specific RRE target sequences to stimulate transcription, or 2) by interacting with cellular factors and/or other viral factors to enhance transcription indirectly. The involvement of different cellular factors in various target cells such as B-lymphocytes and endothelial cells may differentially affect HHV-8 pathogenesis and its ability to replicate in these different cell types. Further elucidation of the mechanisms of RTA transactivation will require the identification and characterization of the different cellular and viral factors that are involved in HHV-8 RTA transactivation.
